| Autor: |
Luis M. Pérez-Belmonte, Jaime Sanz-Cánovas, María D. García de Lucas, Michele Ricci, Beatriz Avilés-Bueno, Lidia Cobos-Palacios, Miguel A. Pérez-Velasco, Almudena López-Sampalo, M. Rosa Bernal-López, Sergio Jansen-Chaparro, José P. Miramontes-González, Ricardo Gómez-Huelgas |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Endocrinology, Vol 13 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1664-2392 |
| DOI: |
10.3389/fendo.2022.851035 |
| Popis: |
BackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsIn this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.ResultsA total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
